Products for Research Use Only

O-7460

CAT: 0804-HY-120851Size: 500 μg (10.45 mM x 100 μL in Methyl Acetate)Dry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-120851Size:500 μg (10.45 mM x 100 μL in Methyl Acetate)
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
O-7460 is a potent and selective DAGLα inhibitor, with an IC50 of 0.69 μM. O-7460 shows selectivity over onoacylglycerol lipase (MAGL), human CB1 and CB2 cannabinoid receptors. O-7460 can decrease HFD-caused an up-regulation of 2-AG levels[1].
CAS Number
1572051-31-0
UNSPSC
12352211
Hazard Statement
H225-H319-H336
Target
Cannabinoid Receptor; DAGL
Type
Reference compound
Related Pathways
GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/o-7460.html
Concentration
10.45 mM * 100 μL in Methyl acetate
Purity
95.0
Solubility
10 mM in DMSO
Smiles
CC(OCC(COP(F)(C)=O)OC(CCCCCCC/C=C\CCCCCCCC)=O)C
Molecular Formula
C25H48FO5P
Molecular Weight
478.62
Precautions
P210-P233-P240-P241-P242-P243-P261-P264-P271-P280-P303+P361+P353-P304+P340-P305+P351+P338-P370+P378-P403+P233-P403+P235-P405-P501
References & Citations
[1]Bisogno T, et, al. A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects. Br J Pharmacol. 2013 Jun;169 (4) :784-93.
Shipping Conditions
Blue Ice
Storage Conditions
Solution, -20°C, 2 years
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
DAGLα

Popular Products